Cachet Pharmaceutical Co., Ltd. (SHE:002462)
China · Delayed Price · Currency is CNY 13.87
+0.27 (1.99%)
May 8, 2026, 3:04 PM CST
Cachet Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 18,801 | 19,507 | 23,985 | 29,923 | 26,220 | 25,626 |
Other Revenue | 18.41 | 18.41 | 33.96 | 73.25 | - | - |
| 18,819 | 19,525 | 24,019 | 29,996 | 26,220 | 25,626 | |
Revenue Growth (YoY) | -11.45% | -18.71% | -19.93% | 14.40% | 2.32% | 10.19% |
Cost of Revenue | 17,725 | 18,336 | 22,431 | 28,077 | 24,116 | 23,493 |
Gross Profit | 1,095 | 1,189 | 1,588 | 1,919 | 2,104 | 2,133 |
Selling, General & Admin | 509.36 | 533.28 | 882.78 | 1,052 | 1,153 | 1,088 |
Other Operating Expenses | 33.37 | 33.27 | 48.43 | 50.63 | 45.8 | 44.73 |
Operating Expenses | 789.8 | 813.62 | 1,027 | 1,187 | 1,273 | 1,159 |
Operating Income | 304.96 | 375.1 | 561.28 | 732.78 | 831 | 973.49 |
Interest Expense | -82.6 | -82.6 | -129.18 | -166.35 | -188.57 | -164.24 |
Interest & Investment Income | 21.41 | 15.6 | 19.48 | 31.12 | 22.43 | 18.66 |
Currency Exchange Gain (Loss) | - | - | -0.21 | 0.57 | 0.18 | -0.66 |
Other Non Operating Income (Expenses) | 18.34 | -15.85 | -26.62 | -29.13 | -30.96 | -12.17 |
EBT Excluding Unusual Items | 262.11 | 292.25 | 424.74 | 568.99 | 634.08 | 815.08 |
Impairment of Goodwill | -48.94 | -48.94 | -80.41 | -40.05 | -20.21 | -13.71 |
Gain (Loss) on Sale of Investments | 0.31 | -0.03 | 0.04 | -3.5 | -2.63 | -0.52 |
Gain (Loss) on Sale of Assets | 4.25 | 4.31 | 201.43 | 0.85 | 1.67 | 0.74 |
Asset Writedown | -0.6 | -0.18 | -6.14 | -0.3 | -1.88 | -0.21 |
Other Unusual Items | 30.69 | 30.69 | 7.05 | 29.29 | 33.88 | 22.59 |
Pretax Income | 247.81 | 278.09 | 546.7 | 555.28 | 644.91 | 823.98 |
Income Tax Expense | 169.5 | 176.38 | 229.99 | 178.75 | 176.59 | 222.1 |
Earnings From Continuing Operations | 78.32 | 101.71 | 316.71 | 376.53 | 468.31 | 601.88 |
Minority Interest in Earnings | 25 | 9.67 | -158.57 | -126.47 | -171.38 | -248 |
Net Income | 103.31 | 111.38 | 158.14 | 250.06 | 296.94 | 353.88 |
Net Income to Common | 103.31 | 111.38 | 158.14 | 250.06 | 296.94 | 353.88 |
Net Income Growth | -19.76% | -29.57% | -36.76% | -15.79% | -16.09% | 11.43% |
Shares Outstanding (Basic) | 294 | 293 | 293 | 291 | 291 | 292 |
Shares Outstanding (Diluted) | 294 | 293 | 293 | 291 | 291 | 292 |
Shares Change (YoY) | 0.65% | 0.09% | 0.71% | -0.12% | -0.46% | 0.38% |
EPS (Basic) | 0.35 | 0.38 | 0.54 | 0.86 | 1.02 | 1.21 |
EPS (Diluted) | 0.35 | 0.38 | 0.54 | 0.86 | 1.02 | 1.21 |
EPS Growth | -20.28% | -29.63% | -37.21% | -15.69% | -15.70% | 11.01% |
Free Cash Flow | 1,205 | 1,369 | 164.93 | 1,396 | -351.98 | 666.17 |
Free Cash Flow Per Share | 4.10 | 4.67 | 0.56 | 4.80 | -1.21 | 2.28 |
Dividend Per Share | 0.115 | 0.115 | 0.170 | 0.260 | 0.310 | 0.370 |
Dividend Growth | -32.35% | -32.35% | -34.62% | -16.13% | -16.22% | 12.12% |
Gross Margin | 5.82% | 6.09% | 6.61% | 6.40% | 8.03% | 8.32% |
Operating Margin | 1.62% | 1.92% | 2.34% | 2.44% | 3.17% | 3.80% |
Profit Margin | 0.55% | 0.57% | 0.66% | 0.83% | 1.13% | 1.38% |
Free Cash Flow Margin | 6.41% | 7.01% | 0.69% | 4.65% | -1.34% | 2.60% |
EBITDA | 320.86 | 398.49 | 614.64 | 866.17 | 989.04 | 1,114 |
EBITDA Margin | 1.70% | 2.04% | 2.56% | 2.89% | 3.77% | 4.35% |
D&A For EBITDA | 15.9 | 23.39 | 53.36 | 133.39 | 158.03 | 140.26 |
EBIT | 304.96 | 375.1 | 561.28 | 732.78 | 831 | 973.49 |
EBIT Margin | 1.62% | 1.92% | 2.34% | 2.44% | 3.17% | 3.80% |
Effective Tax Rate | 68.40% | 63.42% | 42.07% | 32.19% | 27.38% | 26.96% |
Revenue as Reported | 19,525 | 19,525 | 24,019 | 29,996 | 26,220 | 25,626 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.